^
Association details:
| Biomarker: | NPM-RARA fusion |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | peposertib (M3814) (DNA PK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
THERAPEUTIC TARGETING OF DNA-PKCS WITH M3814 IN COMBINATION WITH CPX-351 (VYXEOS) ACHIEVES PROFOUND LEUKEMIA REDUCTION IN TP53WT AND TP53MUT ACUTE MYELOID LEUKEMIA
Published date:
05/14/2020
Excerpt:
...we co-cultured MOLM-13 TP53wt and TP53mut cells with MSC and treated them with CPX-351 +/- M3814. The combination exhibited higher anti-leukemia effects compared to CPX-351 alone in both MOLM-13 TP53wt and TP53mut cells. Combined treatment also increased apoptosis induction and reduced live cell numbers in relapsed/refractory primary AML samples.
